(13R,15S)-13-METHYL-16-OXA-8,9,12,22,24-PENTAAZAHEXACYCLO[15.6.2.16,9.1,12,15.0,2,7.0,21,25]HEPTACOSA-1(24),2,4,6,17(25),18,20-HEPTAENE-23,26-DIONE

Identification

Name
(13R,15S)-13-METHYL-16-OXA-8,9,12,22,24-PENTAAZAHEXACYCLO[15.6.2.16,9.1,12,15.0,2,7.0,21,25]HEPTACOSA-1(24),2,4,6,17(25),18,20-HEPTAENE-23,26-DIONE
Accession Number
DB06888
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
Not Available
UNII
Not Available
CAS number
Not Available
Weight
Average: 403.4338
Monoisotopic: 403.164439563
Chemical Formula
C22H21N5O3
InChI Key
KBLPHMRCKHFBJB-OLZOCXBDSA-N
InChI
InChI=1S/C22H21N5O3/c1-12-10-13-11-26(12)8-9-27-22(29)15-5-2-4-14(18(15)25-27)19-21(28)23-16-6-3-7-17(30-13)20(16)24-19/h2-7,12-13,25H,8-11H2,1H3,(H,23,28)/t12-,13+/m1/s1
IUPAC Name
(13R,15S)-13-methyl-16-oxa-8,9,12,22,24-pentaazahexacyclo[15.6.2.1⁶,⁹.1¹²,¹⁵.0²,⁷.0²¹,²⁵]heptacosa-1(24),2(7),3,5,17,19,21(25)-heptaene-23,27-dione
SMILES
[H][[email protected]]12CN(CCN3NC4=C(C=CC=C4C3=O)C3=NC4=C(NC3=O)C=CC=C4O1)[[email protected]]([H])(C)C2

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UCyclin-dependent kinase 2Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
16046126
PubChem Substance
99443359
ChemSpider
13174538
BindingDB
50192071
HET
1CD
PDB Entries
2ds1

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.335 mg/mLALOGPS
logP1.86ALOGPS
logP2.14ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)8.26ChemAxon
pKa (Strongest Basic)7.01ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area86.27 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity116.32 m3·mol-1ChemAxon
Polarizability42.01 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.7265
Caco-2 permeable-0.6081
P-glycoprotein substrateSubstrate0.8071
P-glycoprotein inhibitor INon-inhibitor0.5129
P-glycoprotein inhibitor IINon-inhibitor0.9302
Renal organic cation transporterNon-inhibitor0.6758
CYP450 2C9 substrateNon-substrate0.8791
CYP450 2D6 substrateNon-substrate0.6851
CYP450 3A4 substrateSubstrate0.6624
CYP450 1A2 substrateNon-inhibitor0.8396
CYP450 2C9 inhibitorNon-inhibitor0.8381
CYP450 2D6 inhibitorNon-inhibitor0.7095
CYP450 2C19 inhibitorNon-inhibitor0.6885
CYP450 3A4 inhibitorNon-inhibitor0.9182
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7216
Ames testAMES toxic0.5277
CarcinogenicityNon-carcinogens0.7898
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6409 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7555
hERG inhibition (predictor II)Non-inhibitor0.6733
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as quinoxalines. These are compounds containing a quinoxaline moiety, a bicyclic heterocycle made up of a benzene ring fused to a pyrazine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazanaphthalenes
Sub Class
Benzodiazines
Direct Parent
Quinoxalines
Alternative Parents
Indazoles / Alkyl aryl ethers / Pyrazolones / Pyrazines / N-alkylpyrrolidines / Benzenoids / Vinylogous amides / Pyrazoles / Heteroaromatic compounds / Trialkylamines
show 6 more
Substituents
Quinoxaline / Benzopyrazole / Indazole / Alkyl aryl ether / Pyrazine / Pyrazolinone / Benzenoid / N-alkylpyrrolidine / Azole / Heteroaromatic compound
show 18 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Details
1. Cyclin-dependent kinase 2
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Metal ion binding
Specific Function
Serine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis. Phosphorylates CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, N...
Gene Name
CDK2
Uniprot ID
P24941
Uniprot Name
Cyclin-dependent kinase 2
Molecular Weight
33929.215 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on September 15, 2010 15:17 / Updated on November 09, 2017 03:57